India · Delayed Price · Currency is INR Caplin Point Laboratories Earnings Call Transcripts
Fiscal Year 2027
-
Revenue grew 20% year-over-year, with strong U.S. and Latin American performance and robust margins. Expansion into new geographies, automation, and capacity increases are underway, all funded by internal cash flow. Cash reserves are being strategically managed for both yield and future acquisitions.
Fiscal Year 2026
-
Revenue and profits saw robust multi-year growth, with strong cash reserves and zero debt. Expansion in injectables, U.S. and LATAM markets, and disciplined CapEx position the business for sustained double-digit growth and high margins in coming years.
-
Q3 FY26 saw double-digit revenue and profit growth, margin expansion, and strong cash flow. US and Latin America drive future growth, with new product launches, regulatory approvals, and major CapEx investments supporting long-term expansion.
-
Revenue and profit margins grew strongly in H1 FY26, with PAT up 21.6% and EBITDA margin expanding. Expansion in the U.S., Mexico, and Latin America, along with robust cash reserves, positions the company for continued growth and potential acquisitions.
-
Q1 FY2026 delivered 11.7% revenue growth and 20.7% PAT growth, driven by strong Latin America and U.S. performance, robust margins, and a focus on asset-light models. Management projects continued double-digit growth, with new product launches and CapEx supporting future expansion.
Fiscal Year 2025
-
Revenue grew 15% to INR 2,034 crore and PAT rose 17% to INR 541 crore, with record margins and strong liquidity. Caplin Steriles posted INR 366 crore revenue and INR 102 crore EBITDA. Management expects a transition period of 18–24 months before new growth drivers fully materialize.
-
Nine-month FY25 revenue and profits have already surpassed FY23 full-year levels, driven by strong growth in both U.S. and Latin America. Strategic expansion into larger markets, a shift to own-label launches in the U.S., and robust margins position the company for continued growth.
-
Q2 FY25 saw 17.8% revenue growth year-over-year, with strong margins and robust cash accruals. Expansion into oncology, biosimilars, and new geographies is underway, while U.S. B2C efforts and LatAm market entry are expected to drive future growth.
-
Q1 FY25 saw 17% revenue and 20% PAT growth, with gross margin rising to 59.6% and strong cash reserves. U.S. and Latin America drove performance, Caplin Steriles' contribution increased, and major CapEx is planned for injectables and API facilities.